Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PMVP 
Pmv Pharmaceuticals Inc (PMVP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/04/2025: PMVP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $5.67
1 Year Target Price $5.67
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.46% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 55.59M USD | Price to earnings Ratio - | 1Y Target Price 5.67 |
Price to earnings Ratio - | 1Y Target Price 5.67 | ||
Volume (30-day avg) 5 | Beta 1.43 | 52 Weeks Range 0.81 - 1.82 | Updated Date 06/30/2025 |
52 Weeks Range 0.81 - 1.82 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.18 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.24% | Return on Equity (TTM) -32.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -103692633 | Price to Sales(TTM) - |
Enterprise Value -103692633 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.24 | Shares Outstanding 51952700 | Shares Floating 33083986 |
Shares Outstanding 51952700 | Shares Floating 33083986 | ||
Percent Insiders 3.23 | Percent Institutions 78.16 |
Analyst Ratings
Rating 3 | Target Price 5.67 | Buy 1 | Strong Buy 4 |
Buy 1 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Pmv Pharmaceuticals Inc
Company Overview
History and Background
PMV Pharmaceuticals, Inc. is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies that target p53. Founded in 2013, the company focuses on restoring p53 activity in tumors with p53 mutations.
Core Business Areas
- Oncology Drug Development: PMV Pharmaceuticals focuses on discovering and developing small molecule therapies that activate mutant p53 proteins in cancer cells. Their main efforts are in clinical trials for their leading drug candidates.
Leadership and Structure
David M. Reese is the President and CEO. The company is structured around research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- PCM-012: PCM-012 is PMV Pharmaceuticals' lead clinical-stage candidate, a small molecule designed to selectively bind to and stabilize mutant p53 protein, restoring its tumor-suppressing activity. There is no current market share as the product is in clinical development. Competitors are other companies exploring similar p53 pathways but with different methods or targets.
Market Dynamics
Industry Overview
The oncology market is a large and rapidly growing field. Precision oncology, focusing on targeted therapies based on genetic mutations, is a significant trend.
Positioning
PMV Pharmaceuticals is positioned within the precision oncology market with its unique approach to activating mutant p53. Its competitive advantage lies in its specific targeting mechanism.
Total Addressable Market (TAM)
The total addressable market is significant due to the prevalence of p53 mutations in cancers. Estimates suggest hundreds of thousands of patients could benefit, representing a multi-billion dollar market. PMV is positioned to capture a portion of this TAM upon successful commercialization of its drugs.
Upturn SWOT Analysis
Strengths
- Novel approach to p53 activation
- Experienced management team
- Strong intellectual property portfolio
- Clinical-stage product candidate
Weaknesses
- Reliance on single product candidate
- Limited financial resources compared to larger pharmaceutical companies
- Clinical trial risks
- Lack of approved products and revenue
Opportunities
- Successful clinical trials and regulatory approvals
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Development of next-generation p53 activators
Threats
- Clinical trial failures
- Competition from other oncology therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MRTX
- ARRY
- GILD
Competitive Landscape
PMV Pharmaceuticals faces competition from established oncology companies with approved therapies and those developing novel targeted therapies. The company differentiates itself through its unique approach to activating mutant p53.
Growth Trajectory and Initiatives
Historical Growth: PMV Pharmaceuticals' growth is linked to the progression of its clinical programs. Stock fluctuations reflect clinical trial results.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and potential commercialization of PCM-012 and other pipeline candidates. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include enrolling patients in clinical trials for PCM-012 and expanding the pipeline with preclinical programs.
Summary
PMV Pharmaceuticals is a clinical-stage company with a promising but risky approach to cancer treatment. The company's success hinges on positive clinical trial outcomes for its lead candidate. Its focus on p53 activation is innovative, but it must overcome challenges related to clinical development and competition. Recent initiatives to advance clinical trials are encouraging but funding and results are vital for long term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- PMV Pharmaceuticals Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Data is based on available information and may be subject to change. Market share information is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pmv Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2020-09-25 | Co-Founder, CEO, President & Director Dr. David H. Mack Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 47 | Website https://www.pmvpharma.com |
Full time employees 47 | Website https://www.pmvpharma.com | ||
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.